Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1308A-008 in MSI-H/dMMR stage IV colorectal cancer
2020-005114-18Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quavonlimab, pembrolizumab, favezelimab, vibostolimab and mk-4830 in colorectal cancer (CRC) (5 cohorts), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Mar 2021; status: active.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-005114-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005114-18.